Two monoclonal antibody treatments to slow Alzheimer's disease, lecanemab (Leqembi) and donanemab (Kisunla), have been ...

Two monoclonal antibody treatments to slow Alzheimer's disease, lecanemab (Leqembi) and donanemab (Kisunla), have been ...

The next generation of Alzheimer’s therapeutics is moving away from amyloid plaques and tau tangles, offering multiple ...

Kisunla (donanemab-azbt) is a brand-name injection for IV infusion that’s prescribed for certain types of Alzheimer’s disease in adults. As with other drugs, Kisunla can cause side effects ...

Kearney physician Dr. Bradley Rodgers will soon offer Kisunla, the first drug proven to slow the early onset of Alzheimer’s.

Kisunla (donanemab-azbt) is a brand-name injection for IV infusion prescribed for Alzheimer’s disease. Kisunla has no known interactions with alcohol, other drugs, or supplements. However ...

Kisunla (donanemab-azbt) is a prescription drug used to treat Alzheimer’s disease. The drug is given as an intravenous (IV) infusion by a healthcare professional. You’ll typically receive a ...

Leqembi and Kisunla don’t just reduce amyloid plaques that are implicated in Alzheimer’s disease. According to new research, ...

A Hartsville hospital patient is among the first in the United States to receive a new treatment that helps slow the ...

Eli Lilly said it will spend $1.8 billion to boost production in Ireland of its popular diabetes and weight-loss drugs, along with ingredients for its recently approved Alzheimer’s treatment, Kisunla.

Demand for Eli Lilly’s Zepbound and Mounjaro has outstripped supply over the last year, forcing the company to invest heavily ...

Fear of a having a low blood sugar crash dissuades many people with Type 1 diabetes from getting the exercise they need, a ...